Cidara Therapeutics (CDTX) had the highest return in Q2 2015 by a mid-cap US stock, returning 1,652.5%.
| ASSET | QUARTER | % RETURN |
|---|---|---|
Cidara Therapeutics (CDTX) | Q2 2015 | 1,652.5% |
CleanSpark (CLSK) | Q2 2015 | 791.08% |
Sarepta Therapeutics (SRPT) | Q2 2015 | 115.36% |
Galapagos NV ADR (GLPG) | Q2 2015 | 115.35% |
Sharplink Gaming (SBET) | Q2 2015 | 69.75% |
SolarEdge Technologies (SEDG) | Q2 2015 | 65.75% |
Ultragenyx (RARE) | Q2 2015 | 62.52% |
Halozyme Therapeutics (HALO) | Q2 2015 | 58.23% |
Caesars Entertainment (CZR) | Q2 2015 | 56.4% |
NexGen Energy (NXE) | Q2 2015 | 51.91% |
Walker & Dunlop (WD) | Q2 2015 | 50.82% |
Veracyte (VCYT) | Q2 2015 | 49.53% |
Wingstop (WING) | Q2 2015 | 49.47% |
Light & Wonder (LNW) | Q2 2015 | 47.58% |
LeMaitre Vascular (LMAT) | Q2 2015 | 46.4% |
Globant (GLOB) | Q2 2015 | 43.95% |
Golar LNG (GLNG) | Q2 2015 | 41.34% |
Supernus Pharmaceuticals (SUPN) | Q2 2015 | 40.33% |
Travere Therapeutics (TVTX) | Q2 2015 | 37.95% |
Ambarella (AMBA) | Q2 2015 | 37.41% |
Repligen (RGEN) | Q2 2015 | 36.47% |
Tecnoglass (TGLS) | Q2 2015 | 35.95% |
SSR Mining (SSRM) | Q2 2015 | 35.34% |
KBR (KBR) | Q2 2015 | 35.25% |
Cal-Maine Foods (CALM) | Q2 2015 | 34.24% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
